Raymond James & Associates’s BioTelemetry, Inc. BEAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-17,662
| Closed | -$1.27M | – | 4182 |
|
|
2020
Q4 | $1.27M | Sell |
17,662
-40,097
| -69% | -$2.1M | ﹤0.01% | 2180 |
|
|
2020
Q3 | $2.63M | Sell |
57,759
-30,161
| -34% | -$1.26M | ﹤0.01% | 1589 |
|
|
2020
Q2 | $3.97M | Sell |
87,920
-2,801
| -3% | -$126K | 0.01% | 1337 |
|
|
2020
Q1 | $3.49M | Buy |
90,721
+9,099
| +11% | +$419K | 0.01% | 1247 |
|
|
2019
Q4 | $3.78M | Sell |
81,622
-6,371
| -7% | -$276K | ﹤0.01% | 1433 |
|
|
2019
Q3 | $3.58M | Sell |
87,993
-57,023
| -39% | -$2.46M | 0.01% | 1425 |
|
|
2019
Q2 | $6.98M | Sell |
145,016
-10,201
| -7% | -$536K | 0.01% | 1049 |
|
|
2019
Q1 | $9.72M | Buy |
155,217
+71,513
| +85% | +$4.91M | 0.01% | 840 |
|
|
2018
Q4 | $5M | Sell |
83,704
-8,630
| -9% | -$518K | 0.01% | 1103 |
|
|
2018
Q3 | $5.95M | Buy |
92,334
+6,996
| +8% | +$390K | 0.01% | 1114 |
|
|
2018
Q2 | $3.84M | Buy |
85,338
+8,971
| +12% | +$358K | 0.01% | 1345 |
|
|
2018
Q1 | $2.37M | Buy |
76,367
+30,492
| +66% | +$1M | ﹤0.01% | 1598 |
|
|
2017
Q4 | $1.37M | Sell |
45,875
-259
| -0.6% | -$7.5K | ﹤0.01% | 1938 |
|
|
2017
Q3 | $1.52M | Buy |
46,134
+1,390
| +3% | +$48.1K | ﹤0.01% | 1831 |
|
|
2017
Q2 | $1.5M | Buy |
+44,744
| New | +$1.33M | ﹤0.01% | 1783 |
|
Other funds holding BEAT
Raymond James & Associates's BEAT Position: Q1 2021 in Review
Raymond James & Associates sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 17,662 shares — an estimated $1.27M sold.
Raymond James & Associates first reported a position in BEAT in Q2 2017 and held it in 15 quarters. The position peaked at $9.72M in Q1 2019. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.
- Raymond James & Associates reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
- Raymond James & Associates sold 17,662 BioTelemetry, Inc. shares in Q1 2021, an estimated $1.27M.
- Raymond James & Associates first reported a position in BioTelemetry, Inc. in Q2 2017 and held it in 15 quarters.
- Raymond James & Associates's BioTelemetry, Inc. position peaked at $9.72M in Q1 2019.
- 1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.
Based on Raymond James & Associates's 13F filing for Q1 2021, filed 14 May 2021.